BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 37924152)

  • 1. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.
    Yang Z; Sreenivasan K; Toledano Strom EN; Osse AML; Pasia LG; Cosme CG; Mugosa MRN; Chevalier EL; Ritter A; Miller JB; Cordes D; Cummings JL; Kinney JW
    Alzheimers Res Ther; 2023 Nov; 15(1):190. PubMed ID: 37924152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of plasma amyloid beta
    Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
    Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes.
    De Meyer S; Blujdea ER; Schaeverbeke J; Reinartz M; Luckett ES; Adamczuk K; Van Laere K; Dupont P; Teunissen CE; Vandenberghe R; Poesen K
    Brain; 2024 Mar; 147(3):936-948. PubMed ID: 37787146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
    Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
    Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.
    Koivumäki M; Ekblad L; Lantero-Rodriguez J; Ashton NJ; Karikari TK; Helin S; Parkkola R; Lötjönen J; Zetterberg H; Blennow K; Rinne JO; Snellman A
    Alzheimers Res Ther; 2024 May; 16(1):112. PubMed ID: 38762725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease.
    Yakoub Y; Ashton NJ; Strikwerda-Brown C; Montoliu-Gaya L; Karikari TK; Kac PR; Gonzalez-Ortiz F; Gallego-Rudolf J; Meyer PF; St-Onge F; Schöll M; Soucy JP; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
    Alzheimers Dement; 2023 Dec; 19(12):5620-5631. PubMed ID: 37294682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
    Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
    Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
    Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic Indicators of Health Predict Alzheimer's Disease Biomarker Levels and Dementia Risk.
    Dark HE; Paterson C; Daya GN; Peng Z; Duggan MR; Bilgel M; An Y; Moghekar A; Davatzikos C; Resnick SM; Loupy K; Simpson M; Candia J; Mosley T; Coresh J; Palta P; Ferrucci L; Shapiro A; Williams SA; Walker KA
    Ann Neurol; 2024 Feb; 95(2):260-273. PubMed ID: 37801487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dynamics of plasma biomarkers across the Alzheimer's continuum.
    Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
    Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.
    McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S
    J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.
    Chatterjee P; Doré V; Pedrini S; Krishnadas N; Thota R; Bourgeat P; Ikonomovic MD; Rainey-Smith SR; Burnham SC; Fowler C; Taddei K; Mulligan R; Ames D; Masters CL; Fripp J; Rowe CC; Martins RN; Villemagne VL;
    J Alzheimers Dis; 2023; 92(2):615-628. PubMed ID: 36776057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease.
    Snellman A; Ekblad LL; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Pietilä E; Koivumäki M; Helin S; Karrasch M; Zetterberg H; Blennow K; Rinne JO
    Neurobiol Dis; 2023 Jul; 183():106175. PubMed ID: 37268240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of plasma neurofilament light chain and glial fibrillary acidic protein in subjective cognitive decline and mild cognitive impairment.
    Mazzeo S; Ingannato A; Giacomucci G; Bagnoli S; Cavaliere A; Moschini V; Balestrini J; Morinelli C; Galdo G; Emiliani F; Piazzesi D; Crucitti C; Frigerio D; Polito C; Berti V; Padiglioni S; Sorbi S; Nacmias B; Bessi V
    Neurol Sci; 2024 Mar; 45(3):1031-1039. PubMed ID: 37723371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of plasma Aβ42/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status.
    Bun S; Ito D; Tezuka T; Kubota M; Ueda R; Takahata K; Moriguchi S; Kurose S; Momota Y; Suzuki N; Morimoto A; Hoshino Y; Seki M; Mimura Y; Shikimoto R; Yamamoto Y; Hoshino T; Sato Y; Tabuchi H; Mimura M
    Alzheimers Res Ther; 2023 Sep; 15(1):149. PubMed ID: 37667408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline.
    Peretti DE; Boccalini C; Ribaldi F; Scheffler M; Marizzoni M; Ashton NJ; Zetterberg H; Blennow K; Frisoni GB; Garibotto V
    Brain; 2024 Jun; ():. PubMed ID: 38940331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between topological efficiency of white matter structural connectome and plasma biomarkers across the Alzheimer's disease continuum.
    Zhang M; Chen H; Huang W; Guo T; Ma G; Han Y; Shu N
    Hum Brain Mapp; 2024 Jan; 45(1):e26566. PubMed ID: 38224535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.